Drugs / GHK-Cu
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07437586 | Feb 2026 → Feb 2027 expected | — | Hudson Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GHK-Cu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07437586 ↗ |
| Known as | Copper(II)-peptide complex | “GHK-Cu Gel (Copper(II)-peptide complex)” NCT07437586 ↗ |
| Modality | Peptide | “GHK-Cu (a copper(II)-peptide complex)” NCT07437586 ↗ |
| Route | Topical | “This study will evaluate whether a topical gel containing GHK-Cu” NCT07437586 ↗ |